Should Investors Worry About the Federal Investigation of Cassava?
Cassava Sciences (NASDAQ: SAVA) has been embroiled in a controversy for several months related to allegations that it falsified data for its experimental Alzheimer's disease drug simufilam. Last month, the company revealed that it's the subject of a federal investigation. In this Motley Fool Live video recorded on Nov. 16, Fool contributors Keith Speights and Brian Orelli discuss whether investors should worry about this development.
Source Fool.com